TrialGynecologic oncology2019

53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.

Rachel M Hurley et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.